Company Filing History:
Years Active: 2009-2018
Title: Cho-Lea Tso: Innovator in Kidney Cancer Immunotherapy
Introduction
Cho-Lea Tso is a prominent inventor based in Torrance, CA (US), known for his significant contributions to the field of immunotherapy for kidney cancer. With a total of 4 patents, Tso has focused on developing innovative solutions aimed at improving treatment outcomes for patients suffering from renal cell cancers.
Latest Patents
One of Tso's latest patents is a kidney-specific tumor vaccine directed against the kidney tumor antigen G-250. This invention provides an anti-cancer immunogenic agent that elicits an immune response specifically directed against renal cell cancers expressing the G250 antigenic marker. The preferred immunogenic agents comprise a chimeric molecule that includes a kidney cancer-specific antigen (G250) attached to a granulocyte-macrophage colony-stimulating factor (GM-CSF). These agents are useful in various treatment modalities, including protein vaccination, DNA vaccination, and adoptive immunotherapy.
Career Highlights
Cho-Lea Tso is affiliated with the University of California, where he continues to advance his research in cancer immunotherapy. His work has garnered attention for its potential to revolutionize treatment approaches for kidney cancer patients.
Collaborations
Tso collaborates with notable professionals in the field, including Arie S Belldegrun, who is also recognized for her contributions to cancer research and treatment.
Conclusion
Cho-Lea Tso's innovative work in developing targeted immunotherapies for kidney cancer exemplifies the potential of scientific research to improve patient outcomes. His contributions are paving the way for new treatment options in the fight against cancer.